Loading
Every dated change on the records linked to Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Involved-field boost non-inferior (5-year EFS 82.
Carboplatin radiosensitisation improved event-free and overall survival in group 3 high-risk medulloblastoma; isotretinoin maintenance was stopped for futility.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.